Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2F5 + 2G12 + 4E10
- Development stage
- Unknown
- Lead developer
- Polymun Scientific
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Topical, Intravenous
01
Overview
This drug is a combination of three broadly neutralizing fully human monoclonal antibodies (2F5, 2G12, and 4E10) developed by Polymun Scientific for the treatment and prevention of HIV-1 infection. These antibodies target critical components of the HIV-1 envelope glycoproteins to block viral entry into host cells. Specifically, 2F5 and 4E10 bind to the membrane-proximal external region (MPER) of the gp41 glycoprotein, while 2G12 targets a carbohydrate-dependent epitope on the gp120 glycoprotein. The combination has been evaluated in clinical trials for systemic administration and as a topical vaginal microbicide gel formulation known as MABGEL. These antibodies are also widely utilized as reference reagents in global HIV research due to their well-characterized neutralizing profiles.
- Brand names
- MABGEL
- Other names
- HIV Antibodies (C2F5, C2G12, C4E10)2F5 + 2G12 + 4E10fully human monoclonal antibodies
02
Targets
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)MPER (Human immunodeficiency virus type 1 envelope glycoprotein 41)KYNU (Kynureninase)gp120 glycan shield (HIV-1 gp120 glycan shield)OST48 (Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit (DDOST))spliceosome (NineTeen Complex)
Beyond the preview
Go deeper on 2F5 + 2G12 + 4E10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2F5 + 2G12 + 4E10.